Flow Diverters Market Size, Share, Growth, Trends, and Global Industry Analysis: By Device Design Type (Single-layer Braided Flow Diverters, Dual-layer Flow Diverters), By Intracranial Aneurysms Type (Small/Distal  Aneurysms, Large Aneurysms), By End User (Hospitals/University Hospitals, Neurology Clinics, Others), By Institution Type (Public Hospitals, Private Hospitals) and Region Forecast 2020-2031

Flow Diverters Market size was valued at US$ 372.5 million in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 11.3% from 2024 to 2030. The market are specialized medical devices used in the treatment of complex intracranial aneurysms. These devices work by redirecting blood flow away from the aneurysm sac, promoting thrombosis within the aneurysm and eventual occlusion. The market for flow diverters encompasses various types of devices designed for different aneurysm morphologies and locations within the cerebral vasculature. The flow diverters market growth is driven by factors such as the increasing prevalence of intracranial aneurysms, advancements in minimally invasive neurovascular procedures, and the rising adoption of endovascular treatments.

According to the Brain Aneurysm Foundation, an estimated 6.5 million people in the United States have an unruptured brain aneurysm, with about 30,000 rupturing each year. The COVID-19 pandemic initially impacted the market due to the postponement of elective procedures, but the market has since shown resilience and recovery. However, challenges such as the high cost of flow diverter devices, stringent regulatory approval processes, and the need for specialized training for device deployment may impact market growth to some extent.

Flow Diverters Market Key Developments:

• On April 21, 2021, Medtronic plc announced that it received approval from the United States Food and Drug Administration (FDA) for Pipeline™ Flex Embolization Device with Shield Technology™. Medtronic developed Shield Technology, a proprietary breakthrough in biomaterial science, to advance flow diversion therapy by introducing the first surface-modified implant device which demonstrates reduction in material thrombogenicity, a reduction in the tendency of the surface treatment material to create clots.
• On August 24, 2020, Stryker announced the launch of the Surpass Evolve Flow Diverter following approval by the U.S. Food and Drug Administration. It was the first 64-wire cobalt chromium flow diverter in the U.S. designed to re-direct blood flow and promote aneurysm healing.